Prevalence of epilepsy in Saudi pregnant women and possible effects of anti-epileptic drugs on pregnancy outcomes

Mona H. AlSheikh, PhD.

ABSTRACT

The objectives: To determine the prevalence of epilepsy in Saudi pregnant women and estimate the frequency of seizure types in suffering individuals using different anti-epileptic drug modalities. It also aimed to report the teratogenic effects of anti-epileptic drugs as observed in neonates.

Methods: This prospective study was conducted at King Fahd University Hospital from June 2018 to July 2019. Sixty-eight pregnant women diagnosed with epilepsy were included in this study. Seizure types and their frequencies were recorded along with anti-epileptic drug therapies and their association with fetal/neonatal malformations.

Results: Out of 68 epileptic pregnant females, 30 (44.1%) experienced focal seizures and 38 (55.9%) experienced generalized seizures. Thirty-nine (57.3%) received monotherapy, 21 (30.9%) received polytherapy and 8 (11.8%) did not take antiepileptic drugs during pregnancy. Thirty-six (52.9%) patients experienced no change in seizure frequency during pregnancy, 19 (27.9%) experienced increase in seizure frequency and 13 (19.1%) showed decreased seizure frequency. The pregnancy outcomes analysis showed 2 (2.9%) intrauterine fetal deaths, whereas 4 (4.9%) neonates showed facial and/or organ malformations.

Conclusion: The frequency of seizures was found to increase in only 27.9% of the pregnant women in the sample. Malformation and mortality rates were higher in fetuses/neonates of patients with generalized seizures. It was observed that for the patient group using monotherapy, the rate of healthy babies was higher than that of the group using polytherapy.

Neurosciences 2020; Vol. 25 (1): 32-37
doi: 10.17712/nsj.2020.1.20190077

From the Department of Physiology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia.

Received 10th September 2019. Accepted 22nd October 2019.

Address correspondence and reprint request to: Dr. Mona H. AlSheikh, Department of Physiology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia. E-mail: monaalsheikh@gmail.com

ORCID ID: https://orcid.org/0000-0003-3095-1969
Epilepsy is defined as a brain disorder characterized by an enduring predisposition to generate epileptic seizures, with cognitive, neurobiological, psychological, and social consequences. An epileptic seizure is “a transient occurrence of signs and symptoms due to abnormal excessive or synchronous neuronal activity in the brain”. According to the World Health Organization (WHO), it is the second most burdensome neurological disorder that can cause cognitive, neurobiological and psychosocial abnormalities in the suffering individuals. In women with epilepsy (WWE), disruption of menstruation cycle, fertility, pregnancy, fetus development, menopause and sexual dysfunction has been reported. The condition becomes more critical when WWE become pregnant. It has been estimated that the maternal death rate for this group is 10 times higher as compared to normal pregnancy cases. Moreover, the frequent seizures during pregnancy have been known to jeopardize the cognitive and physical development of the fetus. Thus, epilepsy is not only harmful for the mother but may also pose potentially worse consequences for the fetus.

The management of seizures through anti-epileptic drugs (AEDs) in pregnant WWE is a challenging task because during the risk-benefit assessment, the needs of the suffering WWE against the potential adverse effects of AEDs on the fetus need to be taken into account as well. Several studies suggest the association of AEDs with congenital malformations which put physicians in a difficult spot. In this challenging situation, the attending physician is expected to choose between the available treatment options (mono- or polytherapy) during pregnancy. Therefore, the most critical issue is the regulation of the minimum effective dose of AEDs during pregnancy to prevent any damage to the fetus from seizures as well as AEDs.

A plethora of evidence has reported the prevalence of epilepsy and its possible outcomes in the general population. However, less is known about the prevalence of epilepsy in Saudi pregnant women, the association of AEDs with the frequency of seizures and their impact on fetal development. The quantification of epileptic pregnant patients and their pregnancy outcomes is important in order to provide optimal counseling and patient care. Therefore, the aims of this study were multifold: (1) to determine the prevalence of epilepsy in pregnant females, (2) to estimate the frequency of seizure types in suffering individuals using different anti-epileptic drug modalities, (3) to assess pregnancy outcomes and possible birth defects in WWE taking monotherapy, polytherapy or no therapy during pregnancy.

**Methods.** **Study Population.** This prospective study was conducted in a Tertiary Care Teaching and Referral Hospital, King Fahd University Hospital, Khobar, Saudi Arabia between June 2018 to July 2019. This hospital has the highest number of antenatal attendances in the eastern province for both normal and high-risk cases. Pregnant patients with active epilepsy admitted to the Obstetrics and Gynecology outpatient clinic and those seeking follow-up from our outpatient clinic were recruited in this study. Inclusion criteria was patients with active epilepsy and on treatment and those who had at least one seizure in the past one year. Patients with single episode of seizure older than one year or seizure from a metabolic or other chronic disorder were excluded from the study. Misdiagnosed seizures such as syncopal attacks, and those who had past history of seizures due to eclampsia were also excluded.

**Instrument.** In this study, patients’ information was collected through a structured questionnaire ‘Questionnaire for Investigation of Epilepsy in Tropical Countries’ which was modified according to the study objectives. The following information was obtained from the history, physical and neurological examination of the patients and through QuadraMed® hospital database (ICD-9 coding system);

- Seizure semiology according to the classification of the International League Against Epilepsy (ILAE); Type and duration of epilepsy; Type and dosage of anti-epileptic drugs; Electroencephalogram (EEG); Magnetic Resonance Imaging (MRI); Frequency of seizures during pregnancy; Fetal or neonatal weight, height, head circumference and presence of malformation.

**Ethical considerations.** The ethical approval was obtained from the institutional review board of Imam Abdulrahman Bin Faisal University after comprehensive review of the study protocols. The purpose of the study was explained to the patients in both oral and written form and informed consent was obtained. All items in the questionnaire were written in both English and Arabic for patients’ convenience and clear understanding. For data collection, additional support was sought from the trainee students of the gynecology and obstetrics department.
Epilepsy in Saudi pregnant women ...

AlSheikh

**Table 1 -** Demographic and clinical characteristics of epileptic patients.

| Variables                        | Monotherapy | Polytherapy | Without medication | P-value |
|----------------------------------|-------------|-------------|--------------------|---------|
| n (%)                            | 39 (57.3)   | 21 (30.9)   | 8 (11.8)           |         |
| Average age ±SD (min-max)        | 28.74±5.8   | 31.2±6.3    | 23.6±2.1          | 0.12    |
| Age of seizure onset (years)     | 17.8±9.1    | 15.7±6.1    | 14.1±8.1          | 0.6     |
| Disease duration (years)         | 12.6±8.9    | 7.3±5.6     | 9.2±9.1           | 0.7     |
| Duration of use of AED (years)   | 11.7±9.07   | 12.3±7.3    | 1.8±2.02          | 0.1     |
| **Seizure semiology, n (%)**     |             |             |                    |         |
| Focal seizure                    | 16 (41.0)   | 11 (52.4)   | 3 (37.5)          | 0.36    |
| Generalized seizure              | 23 (59.0)   | 10 (47.6)   | 5 (62.5)          |         |
| **Number of pregnancies, n (%)** |             |             |                    |         |
| Nulliparous                      | 27 (69.2)   | 14 (66.7)   | 6 (75.0)          | 0.34    |
| Multiparous                      | 12 (30.8)   | 7 (33.3)    | 2 (25.0)          |         |
| **Electroencephalogram, n (%)**  |             |             |                    |         |
| Normal                           | 15 (38.5)   | 5 (23.8)    | 5 (62.5)          | 0.6     |
| Abnormal                         | 24 (61.5)   | 16 (76.2)   | 3 (37.5)          |         |
| **Cerebral imaging (MRI), n (%)**|             |             |                    |         |
| Normal                           | 15 (38.5)   | 5 (23.8)    | 5 (62.5)          | 0.6     |
| Abnormal                         | 24 (61.5)   | 16 (76.2)   | 3 (37.5)          |         |

**Table 2 -** Association between the frequency of seizures during pregnancy with neonatal birth weight, head circumference and height.

| Parameters                  | Seizure frequency in pregnancy: unchanged / decreased / increased | P-value |
|-----------------------------|---------------------------------------------------------------|---------|
| Birth weight (g)            |                                                             |         |
| Unchanged                   | 3064±623 (3105 (1360–4210)                                  | 0.812   |
| Decreased                   | 3324±667 (3410 (1200–4150)                                  |         |
| Increased                   | 3122±675 (3110 (1910–3620)                                  |         |
| Head circumference (cm)     |                                                             |         |
| Unchanged                   | 33.12±7.469 (34.10±7.00)                                    | 0.832   |
| Decreased                   | 34.95±1.990 (34.30±1.38)                                    |         |
| Increased                   | 32.76±2.369 (33.29±2.37)                                    |         |
| Height (cm)                 |                                                             |         |
| Unchanged                   | 48.47±3.441 (50±3.53)                                       | 0.626   |
| Decreased                   | 49.08±3.777 (49±1.51)                                       |         |
| Increased                   | 47.75±3.306 (49±0.52)                                       |         |

**Statistical analysis.** IBM SPSS Statistics package, Version 23.0 (IBM Corp, Armonk, NY, USA) was used for statistical analysis of the data. Numbers and percentages were used to represent categorical measurements, whereas, mean and standard deviation were used for numerical measurements. To compare categorical measurements between the groups, chi-square test was used and to compare the numerical measurements that did not show normal distribution, Mann-Whitney U-test was used. For general comparison between more than two groups that did not show normal distribution, Kruskal-Wallis test was used. Statistical significance was taken as 0.05 in all tests.

**Results.** A total of 5872 patients were screened out of which 157 (2.67%) had either a past history of epileptic events or had an active epilepsy. From these 157 cases, 89 were excluded; 72 had a past history of seizure due to eclampsia, 13 had syncopal attacks misdiagnosed as epilepsy, and 4 had a single seizure episode older than one year. Among the 68 female patients included in the study, the mean age was 27.49±6.8 (min:17, max:35). It was observed that 39 (57.3%) of the patients included in the study received monotherapy, 21 (30.9%) received polytherapy treatment and 8 (11.8%) did not take antiepileptic drugs during pregnancy. Demographic and clinical information of the patients according to the treatment (monotherapy / polytherapy / non-medication) is shown in Table 1. There were 11 patients (16.2%) who used folic acid before pregnancy, 53 patients (77.9%) started folic acid after learning about pregnancy and 4 patients (5.9%) never used folic acid.
The AEDs used were as follows; monotherapy users \[n=39 \text{ (57.3\%)}\]: lamotrigine (LMT)=20, levetiracetam (LEV)=9, carbamazepine (CBZ)=5, oxcarbazepine (OXC)=3, topiramate (TPM)=1, valproic acid (VPA)=1, polytherapy users \[n=21 \text{ (30.9\%)}\]: CBZ + LMT: 6, CBZ + LEV: 6, VPA + LMT: 3, VPA + CBZ: 3, LMT + LEV: 1, TPM + LEV: 1, LEV + OXC: 1, LMT + TPM: 1, \[n=8 \text{ (11.8\%)}\] did not use drugs.

Thirty \(44.1\%\) of the patients had focal seizures and 38 \(55.9\%\) had generalized seizures. There was no statistical difference in terms of the AED groups (polytherapy / monotherapy) used by patients with focal and generalized seizures \(p=0.36\). The EEG was normal in 25 \(36.8\%\) and abnormal (focal slowdown, focal epileptic, secondary generalized epileptic activity) in 43 \(63.2\%\) of the patients. Cerebral imaging (MRI) revealed focal lesions in 13 \(19.1\%\) of the patients. MRI abnormalities included; thrombus in the cerebral vein, signal pathology in the frontal lobe, inactive demyelinating plaques, venous angioma in the frontal lobe, cystic astrocytoma in the temporal lobe, cerebellar atrophy, and/or sequelae of the left frontal tissue.

During pregnancy, 36 \(52.9\%\) of the patients experienced no change in seizure frequency, 19 \(27.9\%\) had increased seizure frequency, and 13 \(19.1\%\) had decreased seizure frequency. The relationship between seizure frequency during pregnancy and neonatal birth weight, head circumference and height was found to be statistically insignificant (Table 2).

Out of the 68 WWE, malformation or stillbirth was observed in 6 \(8.8\%\) of the fetuses/neonates. Out of these 6 cases, 2 had intrauterine death, whereas, malformation (facial, organ or both) was seen in the remaining 4 neonates. The clinical data of these 6 patients experiencing fetal/neonatal abnormalities is given in Table 3 along with their AED regime and its effect on seizure frequency. These abnormalities included; cleft lip and palate, tetralogy of Fallot, atrial septal defect and fetal gastroschisis (Table 3).

**Discussion.** Many regional studies have reported the perceptions and attitude of the general population towards epilepsy\(^{10,12}\) and its prevalence which is known to be roughly 6.54 among every 1000 Saudi individuals.\(^{13}\) The results revealed the prevalence to be 2.67\%, which is significantly lower than some studies\(^{14}\) but higher than the others.\(^{3,15}\) In general, the literature indicates a higher prevalence of epilepsy in under-developed countries as compared to this study.

This lower prevalence rate could be due to differences in study designs in studies of a similar nature. Another probable cause of this result could be that this study was conducted in a tertiary care hospital. It is well known that community-based studies usually report a higher prevalence as compared to hospital-based studies.\(^{16}\) Moreover, women with no or less formal education mostly have a poor health-seeking attitude which could also explain the lower prevalence.\(^{17}\) Another very important factor that could be responsible for the lower prevalence found in this study is the social stigma associated with this disorder.\(^{16}\)

Furthermore, the occurrence of generalized seizure \(55.9\%\) was observed to be more than that of focal seizure \(44.1\%\), which is consistent with the findings of other local studies.\(^{13,18}\) More than half of the pregnant WWE described no change in seizure frequency during pregnancy, which is consistent with the findings of the European and International Registry of Antiepileptic Drugs and Pregnancy.\(^{19}\) Conversely, Patel and Pennell\(^{20}\) reported an increase

---

**Table 3 -** Clinical data of patients experiencing fetal/neonatal malformation or stillbirth.

| Sr # | Seizure Semiology | Medication used | Frequency of seizures during pregnancy | Malformation Category | Malformation Name |
|------|------------------|----------------|----------------------------------------|-----------------------|------------------|
| Patient 1 | Generalized seizure | CBZ 900 mg/day | Increased | Intracranial death | Severe intrauterine growth restriction leading to intrauterine death |
| Patient 2 | Focal seizure | CBZ 1000 mg/day, LMT 200 mg/day | Decreased | Facial malformation | Cleft lip and cleft palate |
| Patient 3 | Generalized seizure | VPA 500 mg/day, LMT 50 mg/day | Unchanged | Intracranial death | Fetal anencephaly leading to still birth |
| Patient 4 | Focal seizure | CBZ 400 mg/day | Unchanged | Organ malformation | Tetralogy of Fallot |
| Patient 5 | Generalized seizure | VPA 1250 mg/day, LMT 800 mg/day | Unchanged | Organ malformation | Atrial septal defect |
| Patient 6 | Generalized seizure | No drug use | Unchanged | Facial + Organ malformation | Fetal gastroschisis along with cleft palate |

CBZ - carbamazepine, VPA - valproic acid, LMT - lamotrigine
in seizure frequency among one-third of their patient population of pregnant women. Unfortunately, there is no local study to compare the results. Additionally, no statistically significant association was observed between the change in seizure frequency and neonatal birth parameters. This could be attributed to the small sample size; otherwise, studies suggest that neonates born to AED taking WWE are usually at higher risk for postnatal complications, such as microcephaly and low birth weight among other issues.\textsuperscript{20}

The goal in the clinical management of epileptic pregnant patients is to reduce seizures with minimal fetal exposure to AEDs. This is often challenging for the attending physician because AEDs are known for their teratogenic effects causing major congenital malformations, deficits in neurocognitive development intrauterine growth retardation and still births.\textsuperscript{5,20,21}

In the current study, major congenital malformations were observed in 6 patients. Two intrauterine deaths were observed in patients suffering from generalized seizures. The rate of stillbirth and congenital malformations in the present study was higher in patients receiving polytherapy as compared to patients receiving monotherapy. A similar trend was observed by Battino and colleagues,\textsuperscript{19} who found more congenital malformations in neonates born to patients on multiple AEDs. Though many works suggest increased likelihood of malformations in polytherapy cases, the association of these malformations to genetic and environmental factors should not be overlooked.

The present study also contained some limitations. First, as it was a hospital-based study, it can be considered that the observed prevalence may not be a true reflection of the whole community. Furthermore, it is highly likely that some women might have not disclosed their epileptic status due to social fear and stigmatization. Thus, it may be difficult to generalize the findings of this study. Second, the sample size of the study was small which may have affected the statistical power of the analysis. Lastly, the serum concentration of AEDs was not measured to explore patient compliance with medication and reliance was placed on verbal information which may not be a completely reliable source.

In conclusion, A 2.67\% prevalence of active epilepsy among pregnant women was observed, with higher occurrence rate of generalized seizures as compared to focal onset. It was found that more than 50\% of the pregnant patients diagnosed with epilepsy did not experience a change in the frequency of seizures during the period of regular drug use. Malformation and mortality rates were higher in fetuses/neonates of patients with generalized seizures. It was observed that the rate of healthy babies for the patient group receiving monotherapy was higher than that compared to the group on polytherapy. The findings of this study may generate research interest in further exploring the pregnancy outcomes of WWE on different AED regimes in our region. Studies of this kind will help physicians to better optimize AEDs and control seizures during pregnancy, thus enhance overall pregnancy outcomes in epileptic women. More reliable results can be achieved by conducting similar but longitudinal studies at multiple centers with a larger sample size.

**Acknowledgements.** I would like to acknowledge Shayma T. Almubayadh and Norah M. Almarri, interns at King Fahd University Hospital for helping me in data collection. I am also thankful to the hospital management and statistics department for granted me access to medical records of the patients. I would also like to thank PaperTrue* English language editing company for their paid English language editing of this manuscript.

**References**

1. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE Official Report: A practical clinical definition of epilepsy. *Epilepsia* 2014; 55: 475-482.
2. Fiest KM, Sauro KM, Wiebe S, Patren SB, Kwon C-S, Dykeman J, et al. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. *Neurology* 2017; 88: 296-303.
3. Watila MM, Beida O, Kwarı S, Nyandaiti NW, Nyandaiti YW. Seizure occurrence, pregnancy outcome among women with active convulsive epilepsy: One year prospective study. *Seizure* 2015; 26: 7-11.
4. Morrell MJ, Montouris GD. Reproductive disturbances in patients with epilepsy. *Clevé Clin J Med* 2004; 71: S19-S24.
5. Viale L, Allotey J, Cheong-See F, Arroyo-Manzano D, McCorr D, Bagary M, et al. Epilepsy in pregnancy and reproductive outcomes: a systematic review and meta-analysis. *Lancet* 2015; 386: 1845-1852.
6. Mawer G, Briggs M, Baker GA, Bromley R, Coyle H, Eatock J, et al. Pregnancy with epilepsy: Obstetric and neonatal outcome of a controlled study. *Seizure* 2010; 19: 112-119.
7. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. *Lancet Neurol* 2012; 11: S03-813.
8. Güveli BT, Rostı RÖ, Güzeltas A, Tuna EB, Atakıl D, Sencer S, et al. Teratogenicity of Antiepileptic Drugs. *Clin Psychopharmacol Neurosci* 2017; 15: 19-27.
9. Camfield P, Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. *Epileptic Disord* 2015; 17: 117-123.
10. Algahtani H, Shirah B, Alzahrani A, Shaheen M. Perception and attitude of the general population towards epilepsy in Jeddah, Saudi Arabia. *J Epilepsy Res* 2019; 9: 42-50.
11. Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. *Epilepsia* 2017; 58: 522-530.
Epilepsy in Saudi pregnant women ... AlSheikh

12. Neyaz HA, Aboauf HA, Alhejaili ME, Alrehaili MN. Knowledge and attitudes towards epilepsy in Saudi families. J Taibah Univ Med Sci 2017; 12: 89-95.
13. Shahid R, Nazish S, Zafar A, Aljafarai D, Alabdali M, Ishaque N, et al. Epidemiological study of epilepsy from a tertiary care hospital in kingdom of Saudi Arabia. Neurosciences 2018; 23: 223-226.
14. Viinikainen K, Heinonen S, Eriksson K, Kälviäinen R. Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy. Epilepsia 2006; 47: 186-192.
15. Katz O, Levy A, Wiznitzer A, Sheiner E. Pregnancy and perinatal outcome in epileptic women: A population-based study. J Matern Neonatal Med 2006; 19: 21-25.
16. Banerjee PN, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsy—A review. Epilepsy Res 2009; 85: 31-45.
17. Sen G, Östlin P. Gender inequity in health: why it exists and how we can change it. Glob Public Health 2008; 3: 1-12.
18. Hamdy NA, Alamgir MJ, Mohammad EGE, Khedr MH, Fazili S. Profile of epilepsy in a regional hospital in Al-qassim, Saudi Arabia. Int J Health Sci 2014; 8: 247-255.
19. Battino D, Tomson T, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. Seizure control and treatment changes in pregnancy: Observations from the EURAP epilepsy pregnancy registry. Epilepsia 2013; 54: 1621-1627.
20. Patel SI, Pennell PB. Management of epilepsy during pregnancy: an update. Ther Adv Neurol Disord 2016; 9: 118-129.
21. Meador KJ, Baker GA, Browning N, Cohen MJ, Clayton-Smith J, Kalayjian LA, et al. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain 2011; 134: 396-404.

Statistics

Excerpts from the Uniform Requirements for Manuscripts Submitted to Biomedical Journals updated November 2003. Available from www.icmje.org

Describe statistical methods with enough detail to enable a knowledgeable reader with access to the original data to verify the reported results. When possible, quantify findings and present them with appropriate indicators of measurement error or uncertainty (such as confidence intervals). Avoid relying solely on statistical hypothesis testing, such as the use of $P$ values, which fails to convey important information about effect size. References for the design of the study and statistical methods should be to standard works when possible (with pages stated). Define statistical terms, abbreviations, and most symbols. Specify the computer software used.